Zactima - Tyrosine Kinase Inhibitor for Treatment of Lung Cancer


NSCLC accounts for about 80% of all lung cancers.



| 1 | 2 | 3 | 4 | 5 | 6 |

Browse More Images - Return to Project




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development